Alkermes Agreement Resolves Lybalvi Patent Lawsuit
An agreement resolves the patent lawsuit covering all dosage strengths of Lybalvi, according to an SEC filing.
Related stories
HAL Q2 Profit Climbs 16%, Revenue Tops Rs 7,600 Crore
Hindustan Aeronautics reported double-digit growth in revenue and profit in Q2 FY27. First-half consolidated revenue exceeded Rs 13,000 crore.
M impact | EQUITY | Nov 12, 2026, 01:04 PM UTC
Sixt Raises 2026 Revenue Guidance to Nearly €4.7 Billion
Sixt reported third-quarter revenue up 11.8% to nearly €1.5 billion and pre-tax earnings up 9% to €281.8 million. It cited strong product demand, high fleet utilization and a lean
M impact | EQUITY | Nov 12, 2026, 01:03 PM UTC
Talanx Raises 2026 Profit Forecast After Q3 Net Income Rises
Third-quarter net income rose to 696 million euros from 591 million euros, while insurance revenue increased 7% to 12.73 billion euros. Talanx also reported nine-month net income o
M impact | EQUITY | Nov 12, 2026, 01:03 PM UTC
Sonova Raises Full-Year Guidance After First-Half Revenue Growth
Revenue rose 6.7% to 1.83 billion Swiss francs in the first half of fiscal 2026/27. Sonova now targets full-year revenue growth of 6–8% and core EBIT growth of 10–13% at constant e
M impact | EQUITY | Nov 12, 2026, 01:03 PM UTC
Tonix Pharmaceuticals CEO Acquires $20,275 in Common Shares
Tonix Pharmaceuticals CEO Seth Lederman acquired $20,275 in common shares.
M impact | EQUITY | Nov 12, 2026, 01:03 PM UTC
NextPlat Reports 35% Gross Margin and 66% Lower Q3 Net Loss
NextPlat reported approximately 35% consolidated gross margins and an approximately 66% year-over-year reduction in net loss for Q3 2026. Gross profit improved nearly 35% year over
M impact | EQUITY | Nov 12, 2026, 01:01 PM UTC